SecBot SecBot

CRSP

CRISPR Therapeutics AG
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. V8· CIK 0001674416 Biotech & Drug DiscoveryGenomics & Gene Editing
$49.71 +0.32 (+0.65%)
Oct 26 4:00 PM ET · prev $49.39
Market cap
$4.8B
Mid cap
Consensus
Buy
61% Buy or better · 28 analysts
Median target
$80.00
+61% · range $44.00–291.00
Next earnings
Nov 4
in 9 days · EPS est. −$1.06
1 year
−24.4%
from $65.72 · Oct 27
30 days
−8.1%
from $54.09
52-week range
$44.34–65.72
−24% from high · low Mar 30
Avg volume 20D
1.50M
shares / day
Short interest
18.68M
≈19.3% of shares · −2.0%
Days to cover
9.6
at average volume
Insider net
-$6.7M
0 buyers · 6 sellers · since Mar 16
New fund stakes
1
Q2 2026 13F · 0 exits
SecBot read MIXED 10 reports · 90 days
Balance 3 bearish · 2 bullish · 5 neutral oldest → newest, height = score
Avg score ·High conf. 7/10 ·Next Earnings date, Nov 4, 2026
Strongest BEARISH Three insiders at CRISPR Therapeutics sold a total of ~$3.15M in open-market sales within a week, including…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    6 insiders sold $6.7M.

  • InstitutionsBULLISH

    Q2 2026: 28 added (1 new), 15 trimmed or exited. Largest new: D. E. Shaw & ., $48.7M.

  • AnalystsBULLISH

    17 of 28 rate it Buy or better. Median target $80.00 (+61%).

  • EstimatesRISING

    Current-quarter EPS estimate −$1.187 → −$1.060 over 90 days. 0 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest −2.0% to 18.68M shares. 9.6 days to cover, ≈19.3% of shares.

  • TrendDOWNTREND

    9% below its 50-day average.

  • SocialQUIET

    Crowd 50° (neutral) this week from 1 mention: 0 bullish, 0 bearish. No setup call.

Who's buying

13F· Q2 2026
1
new positions
0
exits
$48.7M
in new stakes
FundMoveSharesValue
UBS Group AGTRIM1,317,499$71.9M
D. E. Shaw & Co., Inc.NEW893,812$48.7M
MORGAN STANLEYADD879,949$48.0M
SUSQUEHANNA INTERNATIONAL GROUP, LLPTRIM427,178$23.3M
Squarepoint Ops LLCADD286,789$15.6M
Jump Financial, LLCDOUBLED277,952$15.2M
DIMENSIONAL FUND ADVISORS LPTRIM275,375$15.0M
GOLDMAN SACHS GROUP INCTRIM272,372$14.9M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

28 analysts
Buy 61% rate it Buy or better
Strong Buy6Buy11Hold11Sell0Strong Sell0
12-month targets · 19 analysts

Price is inside the target range. Median implies +61%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Oct 15, 2026UBS
INITIATE
INITIATENeutral
Aug 31, 2026Citizens
REITERATE
REITERATEMarket Outperform
Aug 31, 2026Needham
REITERATE
REITERATEBuy
Aug 25, 2026Citizens
REITERATE
REITERATEMarket Outperform
Aug 4, 2026Citigroup
MAINTAIN
MAINTAINBuy
Jul 8, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$6.7M
sold · 6 insiders
DateInsiderTypeValue
Oct 19, 2026
Kulkarni Samarth
Chief Executive Officer
SELL$2.4M
Oct 19, 2026
Silver Andrew Jacob
Chief Financial Officer
AWARD25,000 sh
Oct 16, 2026
Kulkarni Samarth
Chief Executive Officer
EXERCISE100,000 sh
Oct 14, 2026
George Simeon
Director
EXERCISE$420.0K
Oct 14, 2026
George Simeon
Director
SELL$720.4K
Oct 14, 2026
Kulkarni Samarth
Chief Executive Officer
SELL$201.9K
Oct 14, 2026
KASINGER JAMES R.
General Counsel and Secretary
SELL$51.2K
Oct 13, 2026
Kulkarni Samarth
Chief Executive Officer
EXERCISE8,333 sh

Earnings setup

Estimates
Nov 4
reports in 9 days
−$1.06
EPS estimate, this quarter
+11%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$1.06-$1.50–-$0.46-0.9%$16.6M
Next Q-$1.16-$2.02–-$0.51-0.5%$17.4M
Current FY🔒 Fresh data, subscribers only
Next FY-$3.55-$5.40–-$0.51-1.6%$154.0M
Reddit
Crowd this week 50° Neutral 0 bullish · 0 bearish
Mentions, 7 days 1 0 in posts · 1 in comments
Recent comments
r/thetagang Neutral 2d ago
Hey there. Thanks for the comments. With regards to the October slowdown it is a combination of volatility slowing down, the consistency of the portfolio, as well as a small change in options management. We know about the volatility, so the consistency has some factors; the first is the heavy concentration in HOOD and CRWD. I have 4 covered calls that are all blown in CRWD. It is up 118.06% YTD. The calls are in the $142.5 - $147.5 range, which means that the unrealized loss on them is $10k
All social signals and their track records

Short side

FINRA· Sep 30, 2026
18,679,198
shares short
-2.0%
vs prior settlement
9.6
days to cover
≈19.3%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 20, 2026 SEC
Three insiders at CRISPR Therapeutics sold a total of ~$3.15M in open-market sales within a week, including the CEO…
CLUSTER — Impact 5/10
Oct 19, 2026 SEC
CRISPR Therapeutics announced the promotion of Andrew J. Silver from SVP, Finance to CFO, effective October 19, 2026…
8-K — Impact 3/10
Oct 19, 2026 Other
CRISPR Therapeutics Announces Chief Financial Officer Transition
ZUG, Switzerland and BOSTON, Oct. 19, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) to
Oct 19, 2026 Insider
Kulkarni Samarth sold 47,837 shares
Chief Executive Officer @ $49.78 ($2.4M)
Oct 19, 2026 Insider
Silver Andrew Jacob was granted 25,000 shares
Chief Financial Officer
Oct 16, 2026 SEC
Three CRSP insiders, including the CEO and a director, sold a combined ~$973K in open-market sales over a two-day…
CLUSTER — Impact 3/10
Oct 16, 2026 Insider
Kulkarni Samarth acquired via exercise 100,000 shares
Chief Executive Officer
Aug 28, 2026 Press
CRISPR Therapeutics presented one-year durability data from its Phase 1a trial of CTX310, an in vivo CRISPR/Cas9 gene…
Impact 7/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 4, 2026
Earnings date
CRSP Q3 2026 Earnings Scheduled — 2026-11-04
Recent
Oct 19, 2026
Press release
CRISPR Therapeutics Announces Chief Financial Officer Transition
ZUG, Switzerland and BOSTON, Oct. 19, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that its Chief Financial Officer…
Oct 2, 2026
Press release
CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026
ZUG, Switzerland and BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), today announced that a poster presentation…
Aug 28, 2026
FDA
CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026
-Data presented in a late-breaking presentation at the European Society of Cardiology (ESC) Congress 2026-
Aug 10, 2026
Earnings date
CRSP Q2 2026 Earnings Scheduled — 2026-08-10
Aug 3, 2026
Earnings
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
ZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second…

SecBot reports

13 filings · 1 press release · 1 bullish · 4 bearish · 8 neutral
All CRSP filing & press-release reports (14)